


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



C-MER 希瑪

C-MER EYE CARE HOLDINGS LIMITED

希瑪眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3309)

PROFIT WARNING

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of C-MER Eye Care Holdings Limited (the “**Company**” which together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Based on the financial information currently available to the Company, it is expected that the Group will record a net loss in the region of HK\$15.0 million to HK\$25.0 million for the six months ended 30 June 2020 (“**1H2020**”) as compared to the net profit of approximately HK\$33.1 million for the same period last year. The expected loss in 1H2020 is primarily due to the impact of COVID-19 in which the Group’s hospitals in mainland China were locked down for up to 6 weeks in the first quarter of 2020. Moreover, the second wave of COVID-19 outbreak in Beijing in June 2020 gave a further blow to our operation in Beijing. Our operation in Shanghai was moderately affected while our operations in Hong Kong, Shenzhen and Kunming were affected to a lesser degree.

The Group is recovering reasonably well from the COVID-19 outbreaks in mainland China and Hong Kong. However, the upcoming performance will depend on whether COVID-19 can be under good control and the degree of slowdown of the economy.

As the Company is still in the process of finalising the results for 1H2020, the information contained in this announcement is based on the management's preliminary review on the unaudited consolidated management accounts of the Group and current information available to the Board and has not been reviewed and confirmed by the Company's auditors or the audit committee of the Board. Shareholders and potential investors of the Company are advised to read carefully the interim results announcement of the Company for 1H2020 which is expected to be published by the end of August 2020.

Shareholders and prospective investors of the Company are advised to exercise caution when dealings in the shares of the Company.

By order of the Board
C-MER Eye Care Holdings Limited
Dr. LAM Shun Chiu Dennis JP
Chairman and Chief Executive Officer and Executive Director

Hong Kong, 7 August 2020

As of the date of this announcement, the Board comprises four executive Directors, namely Dr. LAM Shun Chiu Dennis, Ms. LI Xiaoting, Dr. LEE Yau Wing Vincent and Mr. LI Chunshan and four independent non-executive Directors, namely, Dr. LI Kwok Tung Donald, Mr. MA Andrew Chiu Cheung, Mr. CHAN Chi Leong and Ms. BENTLEY Annie Liang.